Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
n‑cyclopropyl‑4‑(pyrazolo[1,5‑b]pyrindizin‑3‑yl) pyrimidine amine is a small molecule organic compound belonging to the class of aminopyrimidines and derivatives. It has been identified as an inhibitor of cyclin-dependent kinase 2 (CDK2), with reported IC50 values around 120 nM. The compound is primarily investigated for its potential as a kinase inhibitor in drug discovery research. There is no publicly available information on specific clinical indications or advanced development status for this compound at present.[1][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine.